Technical Analysis for MXDHF - Mdxhealth Sa

Grade Last Price % Change Price Change
grade F 1.13 6.10% 0.0650
MXDHF closed up 6.1 percent on Wednesday, October 16, 2019, on 7 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical MXDHF trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Up Strength 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 6.10%
Narrow Range Bar Range Contraction 6.10%
New 52 Week Low Weakness 6.10%
Wide Bands Range Expansion 6.10%
Below Lower BB Weakness 6.10%

Older signals for MXDHF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Poland, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic (methylation) and other molecular technologies, and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for prostate, bladder, kidney, cervical, and brain cancers. Its products include ConfirmMDx, a tissue-based epigenetic test for prostate cancer; SelectMDx, a urine-based mRNA test for prostate cancer; and AssureMDx bladder cancer detection test for patients with unresolved hematuria. The company's preclinical development products comprise InformMDx, a tissue-based gene expression panel for prostate cancer; SelectMDx assay to a point of care testing platform; and MonitorMDx, a blood-based test for prostate cancer. It has collaboration agreement with 3D Signatures Inc. to evaluate prognostic test candidate for prostate cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.
Medicine RTT Cancer Clinical Medicine European Union Prostate Cancer Bladder Cancer Infectious Causes Of Cancer Molecular Diagnostics Gene Expression Cancer Detection Epigenomics Ag Histopathology
Is MXDHF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 6.15
52 Week Low 1.065
Average Volume 3,001
200-Day Moving Average 0.0
50-Day Moving Average 1.8865
20-Day Moving Average 1.6559
10-Day Moving Average 1.4274
Average True Range 0.1851
ADX 10.49
+DI 39.7058
-DI 55.7812
Chandelier Exit (Long, 3 ATRs ) 1.9447
Chandelier Exit (Short, 3 ATRs ) 1.6203
Upper Bollinger Band 2.2998
Lower Bollinger Band 1.012
Percent B (%b) 0.09
BandWidth 77.770397
MACD Line -0.206
MACD Signal Line -0.1699
MACD Histogram -0.0361
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.1300
Resistance 3 (R3) 1.1300 1.1300 1.1300
Resistance 2 (R2) 1.1300 1.1300 1.1300 1.1300
Resistance 1 (R1) 1.1300 1.1300 1.1300 1.1300 1.1300
Pivot Point 1.1300 1.1300 1.1300 1.1300 1.1300
Support 1 (S1) 1.1300 1.1300 1.1300 1.1300 1.1300
Support 2 (S2) 1.1300 1.1300 1.1300 1.1300
Support 3 (S3) 1.1300 1.1300 1.1300
Support 4 (S4) 1.1300